NEW YORK, June 12, 2017 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. OHRP, a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases, today announced that Jason Slakter, MD, Chief Executive Officer, will provide a corporate overview at the 2017 Marcum Microcap Conference, taking place June 15-16 at the Grand Hyatt New York Hotel.
| Ohr Pharmaceutical Presentation Details | |
| Date: | Thursday, June 15 |
| Time: | 2:30pm Eastern Time |
| Location: | Winter Garden, Conference Level |
| Webcast: | http://wsw.com/webcast/marcum5/ohrp |
About Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. (OHRP) is a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases. The company's lead drug candidate, Squalamine lactate ophthalmic solution, 0.2% (also known as OHR-102), is currently being studied using an eye drop formulation in an ongoing clinical trial for the treatment of the wet form of age-related macular degeneration. In addition, Ohr has a sustained-release micro fabricated micro-particle ocular drug delivery platform technology. Additional information on the company may be found at www.ohrpharmaceutical.com.
Contact: Ohr Pharmaceutical Inc. Investor Relations 888-388-2327 ir@ohrpharmaceutical.com LifeSci Advisors, LLC Michael Wood 646-597-6983 mwood@lifesciadvisors.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
